NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a ...

On Monday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.28 which represents a decrease of $-0.21 or -4.68% from the prior close of $4.49. The stock opened at $4.47 and touched a low ...

Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District ...

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Humacyte, Inc. (NASDAQ ...

Humacyte Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -41.67%. The profit margin, also known as the revenue ...

THE LAWSUIT: A class action securities lawsuit was filed against Humacyte, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between May 10, ...

DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...

Insiders who acquired US$775.1k worth of Humacyte, Inc.'s ( NASDAQ:HUMA ) stock at an average price of US$6.64 in ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10 ...

If you incurred significant losses and want to act as the lead plaintiff in the Humacyte class action lawsuit or determine if you are eligible to receive a potential recovery of your losses ...